Translating the neuroscience of alcoholism into clinical treatments: From blocking the buzz to curing the blues

[1]  C. Barr,et al.  Suppression of Alcohol Preference by Naltrexone in the Rhesus Macaque: A Critical Role of Genetic Variation at the μ-Opioid Receptor Gene Locus , 2010, Biological Psychiatry.

[2]  D. Goldman,et al.  Functional CRH variation increases stress-induced alcohol consumption in primates , 2009, Proceedings of the National Academy of Sciences.

[3]  C. Gianoulakis,et al.  Effect of acute ethanol administration on the release of opioid peptides from the midbrain including the ventral tegmental area. , 2009, Alcoholism, clinical and experimental research.

[4]  A. Dickinson,et al.  Parallel and interactive learning processes within the basal ganglia: Relevance for the understanding of addiction , 2009, Behavioural Brain Research.

[5]  R. Spanagel.  Alcoholism: a systems approach from molecular physiology to addictive behavior. , 2009, Physiological reviews.

[6]  D. Couper,et al.  OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. , 2009, Alcoholism, clinical and experimental research.

[7]  Antoine Bechara,et al.  The hidden island of addiction: the insula , 2009, Trends in Neurosciences.

[8]  Aleksey Y. Ogurtsov,et al.  Expansion of the human μ-opioid receptor gene architecture: novel functional variants , 2008, Human molecular genetics.

[9]  N. Singewald,et al.  Substance P in Stress and Anxiety , 2008, Annals of the New York Academy of Sciences.

[10]  D. Hommer,et al.  IMAGING STUDY: Modulation of brain response to emotional images by alcohol cues in alcohol‐dependent patients , 2008, Addiction biology.

[11]  D. Hommer,et al.  Why We Like to Drink: A Functional Magnetic Resonance Imaging Study of the Rewarding and Anxiolytic Effects of Alcohol , 2008, The Journal of Neuroscience.

[12]  D. Couper,et al.  An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. , 2008, Archives of general psychiatry.

[13]  C. Barr,et al.  Mood and Neuroendocrine Response to a Chemical Stressor, Metyrapone, in Buprenorphine-Maintained Heroin Dependence , 2008, Biological Psychiatry.

[14]  P. Hipskind,et al.  Upregulation of Voluntary Alcohol Intake, Behavioral Sensitivity to Stress, and Amygdala Crhr1 Expression Following a History of Dependence , 2008, Biological Psychiatry.

[15]  F. Ferraguti,et al.  Neurokinin 1 receptor antagonism promotes active stress coping via enhanced septal 5-HT transmission , 2007, Neuropsychopharmacology.

[16]  N. Singewald,et al.  Stress-induced release of substance P in the locus coeruleus modulates cortical noradrenaline release , 2007, Naunyn-Schmiedeberg's Archives of Pharmacology.

[17]  John H. Krystal,et al.  Family History of Alcoholism Influences Naltrexone-Induced Reduction in Alcohol Drinking , 2007, Biological Psychiatry.

[18]  L. Ray,et al.  Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. , 2007, Archives of general psychiatry.

[19]  Elizabeth L. Ogburn,et al.  Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. , 2007, Archives of general psychiatry.

[20]  Karmen K. Yoder,et al.  Heterogeneous effects of alcohol on dopamine release in the striatum: a PET study. , 2007, Alcoholism, clinical and experimental research.

[21]  R. Rosenheck,et al.  Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. , 2007, Alcoholism, clinical and experimental research.

[22]  P. Hipskind,et al.  3-(4-Chloro-2-Morpholin-4-yl-Thiazol-5-yl)-8-(1-Ethylpropyl)-2,6-Dimethyl-Imidazo[1,2-b]Pyridazine: A Novel Brain-Penetrant, Orally Available Corticotropin-Releasing Factor Receptor 1 Antagonist with Efficacy in Animal Models of Alcoholism , 2007, The Journal of Neuroscience.

[23]  A. Hansson,et al.  PRECLINICAL STUDY: Region‐specific down‐regulation of Crhr1 gene expression in alcohol‐preferring msP rats following ad lib access to alcohol , 2007, Addiction biology.

[24]  D. Goldman,et al.  Association of a functional polymorphism in the mu-opioid receptor gene with alcohol response and consumption in male rhesus macaques. , 2007, Archives of general psychiatry.

[25]  D. Goldman,et al.  Increased anxiety and other similarities in temperament of alcoholics with and without antisocial personality disorder across three diverse populations. , 2007, Alcohol.

[26]  H. Damasio,et al.  Damage to the Insula Disrupts Addiction to Cigarette Smoking , 2007, Science.

[27]  G. Koob,et al.  Corticotropin-Releasing Factor 1 Antagonists Selectively Reduce Ethanol Self-Administration in Ethanol-Dependent Rats , 2007, Biological Psychiatry.

[28]  A. Lê,et al.  Effects of environmental and pharmacological stressors on c-fos and corticotropin-releasing factor mRNA in rat brain: Relationship to the reinstatement of alcohol seeking , 2006, Neuroscience.

[29]  P. Kalivas,et al.  Development of an alcohol deprivation and escalation effect in C57BL/6J mice. , 2006, Alcoholism, clinical and experimental research.

[30]  G. Koob,et al.  Corticotropin-Releasing Factor within the Central Nucleus of the Amygdala Mediates Enhanced Ethanol Self-Administration in Withdrawn, Ethanol-Dependent Rats , 2006, The Journal of Neuroscience.

[31]  A. C. Hansson,et al.  Variation at the rat Crhr1 locus and sensitivity to relapse into alcohol seeking induced by environmental stress , 2006, Proceedings of the National Academy of Sciences.

[32]  M. Heilig,et al.  Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. , 2006, Pharmacology & therapeutics.

[33]  Maurizio Massi,et al.  REVIEW: Genetically selected Marchigian Sardinian alcohol‐preferring (msP) rats: an animal model to study the neurobiology of alcoholism , 2006, Addiction biology.

[34]  R. Feinn,et al.  Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. , 2006, Drug and alcohol dependence.

[35]  D. Rujescu,et al.  Genetic association of the human corticotropin releasing hormone receptor 1 (CRHR1) with binge drinking and alcohol intake patterns in two independent samples , 2006, Molecular Psychiatry.

[36]  J. Gelernter,et al.  Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. , 2006, Human molecular genetics.

[37]  M. Egli.  Can experimental paradigms and animal models be used to discover clinically effective medications for alcoholism? , 2005, Addiction biology.

[38]  D. Overstreet,et al.  Prior Multiple Ethanol Withdrawals Enhance Stress-Induced Anxiety-Like Behavior: Inhibition by CRF1- and Benzodiazepine-Receptor Antagonists and a 5-HT1a-Receptor Agonist , 2005, Neuropsychopharmacology.

[39]  T. Furmark,et al.  Cerebral Blood Flow Changes After Treatment of Social Phobia with the Neurokinin-1 Antagonist GR205171, Citalopram, or Placebo , 2005, Biological Psychiatry.

[40]  H. Becker,et al.  Effect of pattern and number of chronic ethanol exposures on subsequent voluntary ethanol intake in C57BL/6J mice , 2005, Psychopharmacology.

[41]  Laura Amato,et al.  An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. , 2005, Journal of substance abuse treatment.

[42]  J. Hoenicka,et al.  Clinical predictors of response to naltrexone in alcoholic patients: who benefits most from treatment with naltrexone? , 2005, Alcohol and alcoholism.

[43]  Y. Shaham,et al.  Role of alpha-2 adrenoceptors in stress-induced reinstatement of alcohol seeking and alcohol self-administration in rats , 2005, Psychopharmacology.

[44]  D. Overstreet,et al.  Conceptual framework for the etiology of alcoholism: a “kindling”/stress hypothesis , 2005, Psychopharmacology.

[45]  J. Ott,et al.  Increased Attributable Risk Related to a Functional μ-Opioid Receptor Gene Polymorphism in Association with Alcohol Dependence in Central Sweden , 2005, Neuropsychopharmacology.

[46]  N. Volkow,et al.  Drug addiction: the neurobiology of behaviour gone awry , 2004, Nature Reviews Neuroscience.

[47]  G. Koob,et al.  Enhanced alcohol self-administration after intermittent versus continuous alcohol vapor exposure. , 2004, Alcoholism, clinical and experimental research.

[48]  W. Wurst,et al.  Getting closer to affective disorders: the role of CRH receptor systems. , 2004, Trends in molecular medicine.

[49]  J. Crabbe,et al.  Pharmacogenetic studies of alcohol self-administration and withdrawal , 2004, Psychopharmacology.

[50]  C. Bouza,et al.  Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. , 2004, Addiction.

[51]  G. Koob,et al.  Increased anxiety-like behavior and ethanol self-administration in dependent rats: reversal via corticotropin-releasing factor-2 receptor activation. , 2004, Alcoholism, clinical and experimental research.

[52]  J. Ott,et al.  Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden , 2004, Molecular Psychiatry.

[53]  Alois Saria,et al.  Substance P in the medial amygdala: Emotional stress-sensitive release and modulation of anxiety-related behavior in rats , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[54]  S. Preskorn,et al.  Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression , 2004, Neuropsychopharmacology.

[55]  D. Overstreet,et al.  SB242084, flumazenil, and CRA1000 block ethanol withdrawal-induced anxiety in rats. , 2004, Alcohol.

[56]  D. Overstreet,et al.  Modulation of multiple ethanol withdrawal-induced anxiety-like behavior by CRF and CRF1 receptors , 2004, Pharmacology Biochemistry and Behavior.

[57]  G. Griebel,et al.  Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. , 2003, Trends in pharmacological sciences.

[58]  A. Dagher,et al.  Alcohol promotes dopamine release in the human nucleus accumbens , 2003, Synapse.

[59]  T. Mark,et al.  Understanding US addiction physicians' low rate of naltrexone prescription. , 2003, Drug and alcohol dependence.

[60]  S. Hunt,et al.  Neurokinin-1 Receptor-Expressing Neurons in the Amygdala Modulate Morphine Reward and Anxiety Behaviors in the Mouse , 2003, The Journal of Neuroscience.

[61]  Ting-kai Li,et al.  A comparative study on alcohol-preferring rat lines: effects of deprivation and stress phases on voluntary alcohol intake. , 2003, Alcoholism, clinical and experimental research.

[62]  R. Rimondini,et al.  A temporal threshold for induction of persistent alcohol preference: behavioral evidence in a rat model of intermittent intoxication. , 2003, Journal of studies on alcohol.

[63]  Y. Shaham,et al.  The reinstatement model of drug relapse: history, methodology and major findings , 2003, Psychopharmacology.

[64]  D. Oslin,et al.  A Functional Polymorphism of the μ-Opioid Receptor Gene is Associated with Naltrexone Response in Alcohol-Dependent Patients , 2003, Neuropsychopharmacology.

[65]  G. Koob,et al.  Antagonism of corticotropin-releasing factor attenuates the enhanced responsiveness to stress observed during protracted ethanol abstinence. , 2003, Alcohol.

[66]  S. Hunt,et al.  Lack of self-administration and behavioural sensitisation to morphine, but not cocaine, in mice lacking NK1 receptors , 2002, Neuropharmacology.

[67]  Matthew L. Ho,et al.  Brain metabolic changes during cigarette craving. , 2002, Archives of general psychiatry.

[68]  Majid Ezzati,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[69]  G. Koob,et al.  Increased ethanol self-administration and anxiety-like behavior during acute ethanol withdrawal and protracted abstinence: regulation by corticotropin-releasing factor. , 2002, Alcoholism, clinical and experimental research.

[70]  F. Weiss,et al.  Additive Effect of Stress and Drug Cues on Reinstatement of Ethanol Seeking: Exacerbation by History of Dependence and Role of Concurrent Activation of Corticotropin-Releasing Factor and Opioid Mechanisms , 2002, The Journal of Neuroscience.

[71]  P. Fletcher,et al.  The Role of Corticotropin-Releasing Factor in the Median Raphe Nucleus in Relapse to Alcohol , 2002, The Journal of Neuroscience.

[72]  J. Lachowicz,et al.  The Gerbil Elevated Plus-maze II: Anxiolytic-like Effects of Selective Neurokinin NK1 Receptor Antagonists , 2002, Neuropsychopharmacology.

[73]  P. Gold,et al.  Multiple feedback mechanisms activating corticotropin-releasing hormone system in the brain during stress , 2002, Pharmacology Biochemistry and Behavior.

[74]  D. Overstreet,et al.  Accentuated decrease in social interaction in rats subjected to repeated ethanol withdrawals. , 2002, Alcoholism, clinical and experimental research.

[75]  C. Hodge,et al.  Elevated extracellular CRF levels in the bed nucleus of the stria terminalis during ethanol withdrawal and reduction by subsequent ethanol intake , 2002, Pharmacology Biochemistry and Behavior.

[76]  G. Griebel,et al.  4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related , 2002, The Journal of pharmacology and experimental therapeutics.

[77]  G. Griebel,et al.  4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization. , 2002, The Journal of pharmacology and experimental therapeutics.

[78]  R. Rimondini,et al.  Long‐lasting increase in voluntary ethanol consumption and transcriptional regulation in the rat brain after intermittent exposure to alcohol , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[79]  S. Hunt,et al.  Comparison of the phenotype of NK1R−/− mice with pharmacological blockade of the substance P (NK 1 ) receptor in assays for antidepressant and anxiolytic drugs , 2001, Behavioural pharmacology.

[80]  F. Weiss,et al.  Changes in levels of regional CRF-like-immunoreactivity and plasma corticosterone during protracted drug withdrawal in dependent rats , 2001, Psychopharmacology.

[81]  R. Hen,et al.  Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[82]  G. Higgins,et al.  Inhibition of shock-induced foot tapping behaviour in the gerbil by a tachykinin NK1 receptor antagonist. , 2001, European journal of pharmacology.

[83]  A T McLellan,et al.  Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. , 2000, JAMA.

[84]  M. Papp,et al.  The NK1-receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats , 2000, Behavioural Brain Research.

[85]  A. Wheeldon,et al.  Pharmacological blockade or genetic deletion of substance P (NK1) receptors attenuates neonatal vocalisation in guinea-pigs and mice , 2000, Neuropharmacology.

[86]  C. Heyser,et al.  Excessive Ethanol Drinking Following a History of Dependence: Animal Model of Allostasis , 2000, Neuropsychopharmacology.

[87]  Y. Shaham,et al.  The role of corticotrophin-releasing factor in stress-induced relapse to alcohol-seeking behavior in rats , 2000, Psychopharmacology.

[88]  Stephen P. Hunt,et al.  Rewarding effects of opiates are absent in mice lacking the receptor for substance P , 2000, Nature.

[89]  D. Hoover,et al.  Family history of alcoholism and hypothalamic opioidergic activity. , 1998, Archives of general psychiatry.

[90]  G F Koob,et al.  Transition from moderate to excessive drug intake: change in hedonic set point. , 1998, Science.

[91]  R G Hill,et al.  Distinct mechanism for antidepressant activity by blockade of central substance P receptors. , 1998, Science.

[92]  J A Tischfield,et al.  Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[93]  Stephen P. Hunt,et al.  Altered nociception, analgesia and aggression in mice lacking the receptor for substance P , 1998, Nature.

[94]  G Di Chiara,et al.  A dopamine‐μ1 opioid link in the rat ventral tegmentum shared by palatable food (Fonzies) and non‐psychostimulant drugs of abuse , 1998, The European journal of neuroscience.

[95]  S. File.  Anxiolytic Action of a Neurokinin1 Receptor Antagonist in the Social Interaction Test , 1997, Pharmacology Biochemistry and Behavior.

[96]  J. Calixto,et al.  Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. , 1996, European journal of pharmacology.

[97]  P. Pini.  Addiction , 1996, The Lancet.

[98]  G. Koob,et al.  Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[99]  M. Schuckit,et al.  Alcohol dependence and anxiety disorders: what is the relationship? , 1994, The American journal of psychiatry.

[100]  T. Kaneko,et al.  Immunohistochemical localization of substance P receptor in the central nervous system of the adult rat , 1994, The Journal of comparative neurology.

[101]  F. Bloom,et al.  Oral alcohol self-administration stimulates dopamine release in the rat nucleus accumbens: genetic and motivational determinants. , 1993, The Journal of pharmacology and experimental therapeutics.

[102]  G. Koob,et al.  The effects of 6-hydroxydopamine lesions of the nucleus accumbens and the mesolimbic dopamine system on oral self-administration of ethanol in the rat , 1993, Brain Research.

[103]  C. Kirschbaum,et al.  The 'Trier Social Stress Test'--a tool for investigating psychobiological stress responses in a laboratory setting. , 1993, Neuropsychobiology.

[104]  G. Koob,et al.  Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal , 1993, Brain Research.

[105]  D J Rohsenow,et al.  Alcohol cue reactivity: effects of detoxification and extended exposure. , 1993, Journal of studies on alcohol.

[106]  B. Rounsaville,et al.  Naltrexone and coping skills therapy for alcohol dependence. A controlled study. , 1992, Archives of general psychiatry.

[107]  Rainer Spanagel,et al.  Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway , 1992 .

[108]  R. North,et al.  Opioids excite dopamine neurons by hyperpolarization of local interneurons , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[109]  G. Di Chiara,et al.  Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[110]  G. Di Chiara,et al.  Preferential stimulation of dopamine release in the nucleus accumbens of freely moving rats by ethanol. , 1986, The Journal of pharmacology and experimental therapeutics.

[111]  G A Marlatt,et al.  Understanding and preventing relapse. , 1986, The American psychologist.

[112]  G. Koob,et al.  Low doses of methylnaloxonium in the nucleus accumbens antagonize hyperactivity induced by heroin in the rat , 1985, Pharmacology Biochemistry and Behavior.

[113]  T. Hökfelt,et al.  Chemical anatomy of the brain. , 1984, Science.

[114]  S. Hunt,et al.  Substance P receptors: Localization by light microscopic autoradiography in rat brain using [3H]SP as the radioligand , 1984, Brain Research.

[115]  H. de Wit,et al.  Role of unconditioned and conditioned drug effects in the self-administration of opiates and stimulants. , 1984, Psychological review.

[116]  W. Vale,et al.  Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. , 1982, Science.

[117]  W. Vale,et al.  Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin , 1981 .

[118]  H. L. Altshuler,et al.  Alteration of ethanol self-administration by naltrexone. , 1980, Life sciences.

[119]  K. Fuxe,et al.  On the role of ascending dopamine systems in the control of voluntary ethanol intake and ethanol intoxication , 1979, Pharmacology Biochemistry and Behavior.

[120]  T. Svensson,et al.  Antagonism by alpha methyltyrosine of the ethanol‐induced stimulation and euphoria in man , 1973, Clinical pharmacology and therapeutics.

[121]  W A Hunt,et al.  Relapse rates in addiction programs. , 1971, Journal of clinical psychology.

[122]  D. B. Goldstein,et al.  Alcohol Dependence Produced in Mice by Inhalation of Ethanol: Grading the Withdrawal Reaction , 1971, Science.

[123]  J. Gaddum,et al.  An unidentified depressor substance in certain tissue extracts , 1931, The Journal of physiology.

[124]  A. Cooper,et al.  Predictive Reward Signal of Dopamine Neurons , 2011 .

[125]  M. Schuckit.  An overview of genetic influences in alcoholism. , 2009, Journal of substance abuse treatment.

[126]  P. Buckley.  Neurokinin 1 Receptor Antagonism as a Possible Therapy for Alcoholism , 2009 .

[127]  H. Becker,et al.  Repeated cycles of chronic intermittent ethanol exposure in mice increases voluntary ethanol drinking and ethanol concentrations in the nucleus accumbens , 2008, Psychopharmacology.

[128]  G. Koob,et al.  CRF antagonist reverses the “anxiogenic” response to ethanol withdrawal in the rat , 2005, Psychopharmacology.

[129]  M. Novak,et al.  A mu-opioid receptor single nucleotide polymorphism in rhesus monkey: association with stress response and aggression , 2004, Molecular Psychiatry.

[130]  P. Elliott.  Place aversion induced by the substance P analogue, dimethyl-C7, is not state dependent: implication of substance P in aversion , 2004, Experimental Brain Research.

[131]  D. Oslin,et al.  A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. , 2003, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[132]  G. Wand,et al.  The Mu-Opioid Receptor Gene Polymorphism (A118G) Alters HPA Axis Activation Induced by Opioid Receptor Blockade , 2002, Neuropsychopharmacology.

[133]  G. Di Chiara.  Drug addiction as dopamine-dependent associative learning disorder. , 1999, European journal of pharmacology.

[134]  J. Volpicelli,et al.  Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence , 1997, Psychopharmacology.

[135]  G. Di Chiara,et al.  Ethanol as a neurochemical surrogate of conventional reinforcers: the dopamine-opioid link. , 1996, Alcohol.

[136]  P. Lang.  International Affective Picture System (IAPS) : Technical Manual and Affective Ratings , 1995 .

[137]  N. O'mara,et al.  Naltrexone in the treatment of alcohol dependence. , 1994, The Annals of pharmacotherapy.

[138]  R. Spanagel,et al.  Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[139]  B. Rounsaville,et al.  Naltrexone and coping skills therapy for alcohol de - pendence , 1992 .

[140]  D. Payan.  Neuropeptides and inflammation: the role of substance P. , 1989, Annual review of medicine.

[141]  J. Engel,et al.  Brain Reward Systems and Abuse , 1987 .

[142]  R. Wise,et al.  Brain mechanisms of drug reward and euphoria. , 1985, Psychiatric medicine.

[143]  L. Swanson,et al.  Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. , 1983, Neuroendocrinology.